Lead Product(s) : Cannabidiol,Isoflurane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IHL-216A (cannabidiol) is a CB1 receptor negative allosteric modulator. It is being evaluated in preclinical studies in combination with Isoflurane for the treatment of traumatic brain injury & concussion.
Product Name : IHL-675A
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Cannabidiol,Isoflurane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idronoxil
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Noxopharm Files Septic Shock Treatment Patent for Veyonda®
Details : The patent application is aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.
Product Name : Veyonda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2021
Lead Product(s) : Idronoxil
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable